Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer
- PMID: 14676835
- DOI: 10.1038/sj.onc.1207332
Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer
Abstract
The constitutive activation of nuclear factor kappaB (NFkappaB) helps a variety of tumors to resist apoptosis and desensitizes them to chemotherapy, but the causes are still largely unknown. We have analysed this phenomenon in eight mutant cell lines derived from human 293 cells, selected for NFkappaB-dependent expression of a marker gene, and also in seven tumor-derived cell lines. Conditioned media from all of these cells stimulated the activation of NFkappaB (up to 30-fold) in indicator cells carrying an NFkappaB-responsive reporter. Therefore, secretion of extracellular factors as the cause of constitutive activation seems to be general. The mRNAs encoding several different cytokines and growth factors were greatly overexpressed in the tumor and mutant cells. The pattern of overexpression was distinct in each cell line, indicating that the phenomenon is complex. Two secreted factors whose roles in the constitutive activation of NFkappaB are not well defined were investigated further as pure proteins: transforming growth factor beta2 (TGFbeta2) and fibroblast growth factor 5 (FGF5) were both highly expressed in some mutant clones and tumor cell lines, each activated NFkappaB alone, and the combination was synergistic. Our data indicate that a group of different factors, expressed at abnormally high levels, can contribute singly and synergistically to the constitutive activation of NFkappaB in all of the mutant and tumor cell lines we studied. Since several NFkappaB target genes encode secreted proteins that induce NFkappaB, autocrine loops are likely to be ubiquitously important in the constitutive activation of NFkappaB in cancer. We provide the first evidence of the general, complex, and synergistic activation of NFkappaB in tumor and mutant cell lines through the action of secreted factors and suggest that the same explanation is likely for the constitutive activation of NFkappaB in cancers.
Similar articles
-
Up-regulation of NFkappaB-responsive gene expression by DeltaNp73alpha in p53 null cells.Exp Cell Res. 2006 May 1;312(8):1254-64. doi: 10.1016/j.yexcr.2005.12.013. Epub 2006 Jan 23. Exp Cell Res. 2006. PMID: 16430884
-
Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells.Exp Cell Res. 2004 Sep 10;299(1):227-35. doi: 10.1016/j.yexcr.2004.05.031. Exp Cell Res. 2004. PMID: 15302589
-
Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma.Oncogene. 2007 Mar 1;26(10):1385-97. doi: 10.1038/sj.onc.1209945. Epub 2006 Sep 4. Oncogene. 2007. PMID: 16953224
-
Cytokine overexpression and constitutive NFkappaB in cancer.Cell Cycle. 2004 Sep;3(9):1114-7. Epub 2004 Sep 4. Cell Cycle. 2004. PMID: 15492502 Review.
-
NFkappaB-dependent chemoresistance in solid tumors.Int J Clin Pharmacol Ther. 2002 Aug;40(8):336-47. doi: 10.5414/cpp40336. Int J Clin Pharmacol Ther. 2002. PMID: 12467302 Review.
Cited by
-
Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.Dig Dis Sci. 2004 Aug;49(7-8):1075-83. doi: 10.1023/b:ddas.0000037790.11724.70. Dig Dis Sci. 2004. PMID: 15387324
-
Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer.Cell Death Dis. 2024 Apr 10;15(4):255. doi: 10.1038/s41419-024-06631-8. Cell Death Dis. 2024. PMID: 38600086 Free PMC article.
-
Hyperactivated NF-{kappa}B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells.Mol Cell Biol. 2009 Oct;29(20):5488-504. doi: 10.1128/MCB.01657-08. Epub 2009 Aug 17. Mol Cell Biol. 2009. PMID: 19687301 Free PMC article.
-
Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.Oncotarget. 2017 Jun 20;8(25):39963-39977. doi: 10.18632/oncotarget.18102. Oncotarget. 2017. PMID: 28591716 Free PMC article.
-
IL-1β in Neoplastic Disease and the Role of Its Tumor-Derived Form in the Progression and Treatment of Metastatic Prostate Cancer.Cancers (Basel). 2025 Jan 17;17(2):290. doi: 10.3390/cancers17020290. Cancers (Basel). 2025. PMID: 39858071 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources